Pitolisant to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy: Rationale and clinical utility

Jay T. Guevarra, Robert Hiensch, Andrew W. Varga, David M. Rapoport

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Narcolepsy is a sleep disorder marked by chronic, debilitating excessive daytime sleepiness and can be associated with cataplexy, sleep paralysis and sleep-related hallucina-tions. Pharmacological therapy for narcolepsy primarily aims to increase wakefulness and reduce cataplexy attacks. Pitolisant is a first-in-class agent utilizing histamine to improve wakefulness by acting as an antagonist/inverse agonist of the presynaptic histamine 3 receptor. This review summarizes the clinical efficacy, safety and tolerability of pitolisant in treating the symptoms of narcolepsy. Randomized and observational studies demonstrate pitolisant to be effective in treating both hypersomnolence and cataplexy while generally being well tolerated at prescribed doses. The most common adverse reactions include head-ache, insomnia and nausea.

Original languageEnglish
Pages (from-to)709-719
Number of pages11
JournalNature and Science of Sleep
Volume12
DOIs
StatePublished - 2020

Keywords

  • Cataplexy
  • Excessive daytime sleepiness
  • Histamine 3 receptor
  • Narcolepsy
  • Pitolisant

Fingerprint

Dive into the research topics of 'Pitolisant to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy: Rationale and clinical utility'. Together they form a unique fingerprint.

Cite this